Abstract
Recent literature on pharmaceutical regulations focuses on the apparently increasing scope for intimate relationships between the regulation framework and FDI opportunities in the pharmaceutical industry. This chapter deals with these interactions within the context of the Kingdom of Saudi Arabia (KSA). In 2015, Saudi Arabia was the largest market in the Middle East for drug companies and has one of the most sophisticated healthcare systems in the region. Yet, the Saudi drug regulatory regime have been criticized for having ambiguous procedures from both domestic and foreign companies. In addition, many international agreements have been signed by the Saudi government to encourage and protect foreign direct investment (FDI) in different sectors including the pharmaceutical industry. This research pursued to discover whether the international regulatory regime, based on the theoretical principles of free trade and applied to the international trade relations of KSA, interacts in any manner with the pharmaceutical industry's trends.
Reference35 articles.
1. Workforce localization in the Kingdom of Saudi Arabia: issues and challenges
2. General public knowledge, perceptions and practice towards pharmaceutical drug advertisements in the Western region of KSA
3. Al-Jazirah. (2016, Jan 2). Wafrna 874 milion ala almuatnin wa almugamin [We saved 874 million riyals on citizens and residents]. Al-jazirah Newspaper. Retrieved on June 2, 2016, from: http://www.al-jazirah.com/2016/20160102/rv1.htm